KURA Kura Oncology, Inc.

NASDAQ
$7.77

Kura Oncology, Inc. (KURA) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.81 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.3% since its last earnings release on November 10, 2026.

Kura Oncology Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:02 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.81)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.60

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Kura Oncology, Inc.

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.